Better tools for early detection and accurate staging of pancreatic cancer are needed. The role of 18F-fluorodeoxyglucose (FDG)-PET in this setting is controversial. The results of a large retrospective study analyzing the value of FDG-PET in the diagnosis of pancreatic ductal adenocarcinoma are discussed here.
This is a preview of subscription content, log in via an institution to check access.
References
Tempero, M. A. et al. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J. Natl Compr. Canc. Netw. 10, 703–713 (2012).
Friess, H. et al. Diagnosis of pancreatic cancer by 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 36, 771–777 (1995).
Tang, S. et al. Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis. Eur. J. Radiol. 78, 142–150 (2011).
Matsumoto, I. et al. 18-Fluorodeoxyglucose positron emission tomography does not aide in diagnosis of pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. http://dx.doi.org/10.1016/j.cgh.2012.12.033.
Dibble, E. H. et al. PET/CT of cancer patients: part 1, pancreatic neoplasms. AJR Am. J. Roentgenol. 199, 952–967 (2012).
Kamisawa, T. et al. FDG-PET/CT findings of autoimmune pancreatitis. Hepatogastroenterology 57, 447–450 (2010).
Hartwig, W. et al. CA19–9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann. Surg. Oncol. http://dx.doi.org/10.1245/s10434-012-2809–1.
Kittaka, H. et al. Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer. World J. Surg. 37, 169–178 (2013).
Cameron, K. et al. Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). Abdom. Imaging 36, 463–471 (2011).
Treglia, G., Castaldi, P., Rindi, G., Giordano, A. & Rufini, V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 42, 80–87 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Strobel, O., Büchler, M. FDG-PET is not useful in early pancreatic cancer diagnosis. Nat Rev Gastroenterol Hepatol 10, 203–205 (2013). https://doi.org/10.1038/nrgastro.2013.42
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2013.42
- Springer Nature Limited
This article is cited by
-
[18F] AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma
European Journal of Nuclear Medicine and Molecular Imaging (2023)
-
Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer
European Journal of Nuclear Medicine and Molecular Imaging (2022)
-
PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the “Cancer Integrin” αvβ6 with Ga-68-Trivehexin
European Journal of Nuclear Medicine and Molecular Imaging (2022)
-
There is a world beyond αvβ3-integrin: Multimeric ligands for imaging of the integrin subtypes αvβ6, αvβ8, αvβ3, and α5β1 by positron emission tomography
EJNMMI Research (2021)
-
Molecular imaging of pancreatic neoplasms
Clinical and Translational Imaging (2021)